Business context and reporting period
Maravai LifeSciences Holdings, Inc. filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2023. It supplies life-science products through Nucleic Acid Production and Biologics Safety Testing. Results include Alphazyme from its January 2023 acquisition.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $66.9m | $191.3m | $214.8m | $678.3m |
| Gross profit / margin | $30.2m / 45.1% | $153.1m / 80.0% | $101.2m / 47.1% | $562.6m / 82.9% |
| Operating income (loss) | $(15.4)m | $116.9m | $(24.5)m | $465.0m |
| Net income (loss) | $(15.1)m | $99.7m | $(28.4)m | $403.2m |
| Net income (loss) attributable to Maravai | $(6.5)m | $44.5m | $(13.1)m | $182.6m |
| Adjusted EBITDA | $11.9m | $132.5m | $44.8m | $508.0m |
| Adjusted free cash flow | $0.4m | $116.9m | $5.0m | $479.6m |
For the nine months, operating cash flow was $118.4m, investing cash outflow $109.4m and financing cash outflow $61.6m; cash decreased $52.5m to $579.6m. Cash and cash equivalents were $579.6m at September 30, versus $632.1m at year-end 2022. Current assets were $700.9m and current liabilities $78.3m.
Debt: $534.5m principal outstanding under the term loan (carrying value $525.0m); no revolver borrowings and a $0.5m letter of credit. The term loan bore 8.32% interest and matures in October 2027. The $180m revolving facility remains available subject to its terms. The company reported covenant compliance and a first-lien net leverage ratio below 4.25:1.00. The balance sheet also includes $678.4m payable under the Tax Receivable Agreement (TRA), of which $4.2m is current.
Material changes versus the prior comparable period
- Revenue fell 65.0% in Q3 and 68.3% year to date. Nucleic Acid Production declined 70.7% and 73.4%, respectively; Biologics Safety Testing declined 4.5% and 10.4%.
- Management attributed the main decline to reduced CleanCap demand from COVID-19 vaccine customers. COVID-19-related products and services represented an estimated 22.3% of Q3 revenue and 19.7% year-to-date, versus 66.1% and 70.2% in 2022.
- Lower volume, unfavorable product mix, higher labor and facility costs, and reduced manufacturing throughput weighed on gross margin. SG&A rose 26.2% in Q3 and 22.7% year to date, including increased personnel and facility costs.
- Interest expense increased with higher rates, partly offset by interest income on cash. Stock-based compensation nearly doubled year to date to $25.2m.
- Year-to-date operating cash flow was substantially below 2022, when earnings were much higher. In 2023, operating cash flow benefited from working-capital movements, including a $93.2m reduction in accounts receivable.
Outlook, commentary, risks and unusual items
- Management expects further declines in COVID-19-related revenue, citing weaker demand and customers’ unused inventory; longer-term demand remains uncertain. It also identified customer budget restraint, weaker early-stage biotech funding and economic weakness in Asia, particularly China, as headwinds that could persist into Q4 2023.
- No specific revenue or earnings guidance was provided in the supplied filing text. Management projected 2023 capital expenditures of $50m–$60m, net of anticipated government funding, principally for the Flanders San Diego facility. It stated available cash, operating cash flow and credit access should cover requirements over the next 12 months and beyond.
- In November 2023, the company announced a cost realignment expected to eliminate approximately 15% of its workforce, with estimated one-time costs of about $5m, primarily severance, expected in Q4. Actual costs may differ.
- The Alphazyme acquisition included up to $75m of revenue-based contingent payments; estimated fair value was $5.4m at September 30. Employee retention payments and MyChem retention obligations are additional potential cash costs.
- The $678.4m TRA liability is a substantial long-term cash commitment. A change of control, breach or early termination could accelerate a payment based on the present value of anticipated tax benefits. The filing estimates future TRA payments of approximately $4.2m–$71.5m per year over the next 17 years, subject to assumptions and actual tax benefit realization.
- Other risks include customer and product concentration, continued demand contraction, variable-rate debt, acquisition integration and valuation assumptions, and government funding terms. BARDA support carries conditional priority-access and preferred-pricing obligations for a 10-year period after construction completion. The company reported no material legal proceedings and effective disclosure controls.
Key facts for investors to verify
- Whether COVID-19-related and broader nucleic-acid demand stabilizes, and how customer inventory and spending affect orders.
- Whether Biologics Safety Testing demand and segment profitability recover, particularly in Asia Pacific.
- Cash conversion and the durability of operating cash flow, including the effect of working-capital changes and planned capital spending.
- Debt service exposure to rates and the timing and scale of TRA, lease, retention and contingent-consideration payments.
- The final cost, timing and expected savings from the workforce realignment, and the assumptions supporting Alphazyme performance payments and acquired-asset values.